The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin ...

The Food and Drug Administration is again trying to rehire some staffers who were recently fired amid mass layoffs at the ...

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod ...

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP”) patients was initiated in October 2024 and designed as a ...

The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional ...

A Blue Cross Blue Shield policy will force some patients to self-inject medicine, with potentially dangerous results.

Madison, a twelve-year-old from Illinois, visits a medical clinic every other week to get injections of Xolair, a powerful ...

The FDA has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a post-approval ...

Apr 4, 2025 Apr 4, 2025 Updated Apr 4, 2025 0 Oklahoma’s mental health and addiction infrastructure appears to be on the brink of a breakdown, with looming federal funding freezes, a state ...

In a world where the popularity of weight loss drugs is on the rise, questions on how to obtain them are becoming more ...

It is still being sold under emergency use authorization — unlike mRNA vaccines made by Pfizer and Moderna that have earned full FDA approval for certain age groups. The FDA recently asked Novavax to ...